Following the termination, the Nordic region’s distribution rights will again go back to Oasmia Pharma.
Oasmia Pharma has developed a water soluble formulation of Paclitaxel with the retinoid based platform XR-17.
Paclical, currently in clinical Phase III, is indicated for ovarian cancer.
Other possible indications are non-small cellular lung (NSCL) cancer and malignant melanoma.
Oasmia Pharma is a developer of the next generation cancer drugs based on nanotechnology for human and veterinary use.